Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab for macular edema secondary to branch retinal vein occlusion
ACTRN12607000262404Phase 2Completed
- Sponsor
- Associate Professor Ian McAllister
- Start
- Jul 2007
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in branch retinal vein occlusion (BRVO) comparing Lucentis intravitreal injection with Sham/placebo injection (2 arms). Primary endpoint: Proportion of eyes with improvement in visual acuity by 10 letters. Started Jul 2007; status: completed.
02
Drugs
ranibizumab
03
Conditions
branch retinal vein occlusion (BRVO)
Beyond the preview
Go deeper on ACTRN12607000262404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000262404.